Future for VHL kidney cancer is bright

Von Hippel-Lindau (VHL) disease–associated renal cell carcinoma (RCC) has always been difficult to treat. However, a group of researchers led by Dr William G. Kaelin Jr from the Dana-Faber Cancer Institute and Harvard Medical School in America have discovered treatments including immunotherapy, HIF-2α inhibitors, and potentially CDK4/6 inhibitors for the treatment of VHL-associated RCC. He […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

VHL disease and HIF-2alpha inhibitor

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center in Houston, Texas, USA speaks about the use of  hypoxia-inducible factor (HIF) 2alpha inhibitor for the treatment of renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease. Firstly, Dr Jonasch describes how HIF-2alpha combines with HIF-1beta to act as a transcription factor […]

read more

Hereditary kidney cancer – new syndromes

A recent review of the literature in European Urology summarises the preclinical and clinical data on hereditary renal cancer. There are several well-described hereditary renal cancer syndromes, such as von Hippel-Lindau disease (VHL), a hereditary syndrome that may lead to the development of renal cell carcinoma (RCC). Patients with VHL have a lifetime risk of […]

read more

Potential new treatment strategy for kidney cancer

A research study, published online in eLife, has provided new insight into the mechanisms behind the development of clear cell renal cell carcinoma (ccRCC), which could have implications for how ccRCC is treated. The researchers have discovered that changes or mutations in tumour suppressor genes (VHL, PBRM1, KDM5C, SETD2 and BAP1) responsible for slowing down […]

read more

ESMO 2018: Interviews with the kidney cancer experts

The following video interviews with kidney cancer experts from the USA and Europe were conducted at the recent European Society of Medical Oncology (ESMO) 2018 congress in Munich last month. The interviews cover topics such as a new treatment for VHL-associated kidney cancer, real world effectiveness of pazopanib for renal cell carcinoma (RCC), recommendations for […]

read more

Von Hippel-Lindau (VHL) disease and the risk for kidney cancer

Von Hippel-Lindau (VHL) disease is caused by a change (mutation) in a tumour suppressor gene, called the VHL gene. When the VHL gene is mutated, this can lead to uncontrolled cell growth and the development of cancer. Lack of VHL protein caused by the mutation can also increase the growth of new blood vessels (angiogenesis), causing the […]

read more

Pazopanib for the treatment of von Hippel-Lindau disease

The results from a phase II clinical trial, which demonstrates the potential for first-line treatment with pazopanib as an alternative to surgery in patients with von Hippel-Lindau disease, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week. Thirty-two patients with von Hippel-Lindau disease (VHL) confirmed by genetic testing, […]

read more
Showing all 8 results
  TOP